Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey.

The results of our study showed that, despite being off-label, the DOACs were considered for the treatment of unusual-site venous thromboembolism. The wide variability among different physicians reflected the clinical difficulties and raised the need for more collaborative trials on these disorders.